The purpose of this study is to evaluate the safety and efficacy of an excimer laser in the treatment of patients with lower extremity vascular disease with chronic total occlusions.
The study is a multi center, prospective, non-randomized, open-label study conducted at a minimum of one investigational center. 50 subjects can be enrolled. Follow-up occurs at the end of the procedure in the form of an angiogram to determine if the lesion was crossed. Additional follow-up may not necessary because of the binary nature of the crossing, and also because any future follow-up would be assessing the effectiveness of adjunct therapy, e.g. balloon angioplasty. Long term results are entirely dependent on this subsequent treatment. Because the DABRA crosser only allows adjunct devices to be used, 30-day follow-up measuring the performance of the adjunct therapy might affect the physician's choice of therapy, and compromise the patient's treatment. Therefore, 30-day follow-up, which evaluates the effectiveness of the adjunct therapy, might raise ethical concerns. However, the follow-up can be done by Ankle-Brachial Index, Doppler ultrasound, auscultation, or by discussion of the level of claudication and motion pain with the patient. To evaluate the safety and efficacy of the RA-308 Excimer Laser System and DABRA Catheter for treating subjects with symptomatic infrainguinal lower extremity vascular disease with chronic total occlusions that cannot be crossed with standard guide wires, or lesions where an attempt to cross would, in the opinion of the interventionalist, result in either a subintimal path or a perforation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
64
See information already included in arm description
California Heart & Vascular Clinic
El Centro, California, United States
University of California San Diego
San Diego, California, United States
Merit Health Wesley
Hattiesburg, Mississippi, United States
Crossing the Target Lesion
Crossing the target lesion based on angiographic analysis
Time frame: at time of procedure
Number of Participants With no Device-related Major Adverse Events
Number of participants with no device-related major adverse events as determined by physician evaluation
Time frame: at time of procedure, up to an hour
Number of Participants With Target Lesion Revascularization
Number of participants with target lesion revascularization as determined by physician evaluation
Time frame: 30 days
Number of Participants With Target Lesion Revascularization
Number of participants with target lesion revascularization as determined by physician evaluation
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.